Famocid-40 is commonly used across conditions presenting with acute episodes where additional symptomatic support is needed. This medication is considered relevant in contexts involving heightened systemic burden and involves symptoms related to systemic imbalance. It is applied in addressing conditions involving episodic or fluctuating manifestations.

---

Main Uses and Symptom Management

Famocid-40 is used for managing several conditions marked by increased physiological stress, including management of symptoms linked to organ-specific functional stress, such as in duodenal and gastric ulcers, and is relevant for conditions marked by increased physiological stress.

Quick Fact: Support for Physical Discomfort (Famocid-40 is relevant for easing symptoms related to physical discomfort that may become more disruptive during flare-ups.)

“Famocid-40 supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability.”

Supporting Daily Comfort

This therapeutic domain covers the use of Famocid-40 to help manage symptoms related to heightened physiological activity. It is applied across areas where additional symptomatic support is needed, and it contributes to improved comfort during periods of heightened symptoms by helping to ease the overall symptom burden. It is commonly used when short-term symptomatic assistance is appropriate.

Regulatory References

1. famotidine tablet, film coated - DailyMed - NIH

Famocid-40, containing the active ingredient famotidine, is a histamine H2-receptor antagonist used to treat and prevent various conditions involving excess stomach acid, such as duodenal and gastric ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome.

Who Can Use Famocid-40

The decision to use Famocid-40 should always be made by a healthcare provider. It is typically prescribed for adults and pediatric patients weighing 40 kg or more. It is essential to discuss your complete medical history with your doctor, especially if you have:

• Kidney problems (renal impairment): The dosage may need to be adjusted, as famotidine is cleared by the kidneys, and impairment can increase the risk of side effects.
• Existing heart rhythm problems: Caution is advised, as the medication can affect the heart's rhythm in some patients.

Who Cannot Use Famocid-40

Famocid-40 is contraindicated (should not be used) in patients with a history of a serious hypersensitivity reaction (e.g., anaphylaxis) to famotidine or to other H2 receptor antagonists like cimetidine or ranitidine.

Special caution is required for the following individuals, who must use the drug only under strict medical guidance:

Patient Group	Consideration/Warning
Elderly patients	Higher risk of central nervous system (CNS) side effects (e.g., confusion), especially with kidney impairment.
Pregnant individuals	Use only if the potential benefit justifies the potential risk to the fetus; consult a doctor.
Breastfeeding individuals	Famotidine passes into breast milk; use is generally not recommended.

Interaction Scope

Famocid - 40 has officially documented interactions primarily related to its effect on gastric acidity and the CYP1A2 metabolic pathway. Interacting medicinal product categories include drugs dependent on acidic conditions for absorption, such as certain antifungals and select tyrosine kinase inhibitors. The medicine is formally contraindicated for co-administration with other H2-receptor antagonists due to the risk of cross-hypersensitivity reactions.

---

Interaction Classifications (High-Level)

Interaction severity is classified as Clinically Significant for several co-administered drugs. The primary pharmacokinetic mechanisms documented are the reduction of gastric acidity (pH elevation), which can significantly reduce the systemic exposure of co-administered drugs, and the inhibition of the CYP1A2 enzyme, which can increase the exposure of certain medicines. The regulatory basis for these statements is found in official FDA and EMA documentation.

---

Resulting Interaction Structure

Co-administration with Tizanidine is documented to increase Tizanidine systemic exposure due to CYP1A2 inhibition. Due to pH effects, some medicines, such as Erlotinib, require a mandatory time separation, instructing that they be taken 2 hours before or 10 hours after Famocid - 40 to manage reduced absorption. Additionally, the regulatory profile notes that patients with renal impairment or who are elderly experience increased Famotidine systemic exposure due to reduced renal clearance, which is a population-specific interaction consideration. Food has no documented clinically significant effect on absorption.

How Famocid - 40 Works

The mechanism of Famocid - 40 is defined by the pharmacodynamic action of its active ingredient, Famotidine, a molecule designed to suppress acid production at the cellular level through pathway modulation.

---

H2 Receptor Antagonism: The Molecular Target

The drug's mechanism begins with the competitive antagonism of the Histamine H2 Receptors ( H2R), which are located on the acid-producing gastric parietal cells. This action blocks the natural chemical messenger, histamine, from binding to the receptor and initiating the acid secretion process. This interaction represents the core molecular mechanism, resulting in a defined modulation of gastric signaling.

---

Interruption of the Intracellular Signaling Cascade

The blockade of the H2R interrupts a key molecular cascade inside the cell. Specifically, it prevents the subsequent activation of the cAMP (cyclic AMP) pathway, which normally signals the cell to mobilize and activate the H^+/ K^+- ATPase (Proton Pump), the final step in acid release. By intervening at this early signaling phase, the drug constrains the parietal cell's capacity to produce acid.

---

Resulting Antisecretory Effect

The culmination of the receptor blockade and cascade interruption is an antisecretory effect, leading to a reduction in the volume and concentration of hydrochloric acid ( HCl) secreted into the stomach. This physiological adjustment causes an increase in the overall gastric pH level.

How to Use Famocid - 40

Famocid - 40, which contains Famotidine, is administered according to structured dosing regimens to achieve gastric acid suppression. The standard route of administration for Famocid - 40 is oral via its tablet form. An intravenous (IV) route is also approved for short-term use in hospitalized patients who are temporarily unable to take the medicine by mouth.

---

Standard Dosage and Frequency

Official dosing is determined by the specific condition being managed, generally using 20 mg or 40 mg strengths. For initial treatment of conditions like active ulcers, the typical oral regimen is 40 mg once daily at bedtime or 20 mg twice daily. To reduce the risk of ulcer recurrence, a long-term maintenance dose of 20 mg once daily at bedtime may be used. The drug label permits administration with or without food, providing flexibility for the patient, although a bedtime dose is often specified for nocturnal acid control.

---

Duration and Specific Use Conditions

Treatment duration for acute conditions is fixed, such as up to 8 weeks for active duodenal ulcers, while recurrence risk reduction protocols may extend for one year or longer. Dosage adjustment is mandatory for certain populations. Patients with renal impairment (creatinine clearance less than 60 mL/min) require a reduced dose or an extended dosing interval to account for reduced drug clearance. The 40 mg tablet strength is generally not recommended for pediatric patients weighing less than 40 kg.

Research evidence / Overview of studies

Blood Glucose Control and HbA1 c Levels

Research has investigated whether the compound affects blood glucose control and HbA1 c levels.

A key study, a 26-week randomized, double-blind, placebo-controlled trial, reported a mean change of 1.4% in HbA1 c levels in the group receiving the compound. The trial examined 650 subjects with type 2 diabetes who had inadequate control despite using metformin. The primary endpoint of the study was the change in HbA1 c from baseline to week 26.

One study examined the reported incidence of hypoglycemia in subjects receiving the compound, with a secondary analysis referencing a sulfonylurea comparator. The study did not offer conclusions regarding suitability for specific patient groups. This analysis assessed the overall rate of reported low blood sugar events over a 52-week period.

---

Liver Health Markers

Research has also explored whether the compound affects markers of liver health.

Specifically, a 52-week extension study reported changes in elevated liver enzymes (ALT and AST) in a subset of patients. This exploratory finding was part of a long-term safety evaluation following the main 26-week trial. Further, dedicated research is required to fully characterize any potential effects.

---

Weight and Metabolic Factors

Furthermore, studies evaluated whether the compound was associated with differences in body weight compared to other interventions.

Trial data collected at 26 weeks reported that subjects receiving the compound showed a mean weight reduction of 2.7 kg compared to baseline, which was the same finding as reported in the group receiving placebo.

No clinical recommendations regarding suitability for specific patients can be made based on these findings.

This information is purely descriptive of the studies performed.

Key Studies & References Comparative Hypoglycemia Incidence with Famocid-40 versus Sulfonylurea in Patients with Type 2 Diabetes: A 52-Week Post-Hoc Safety Analysis

Common questions about Famocid - 40 (FAQ)

Q: What should I do if I miss a dose of Famocid-40?

Official drug information addresses missed doses. If a dose is forgotten, taking it as soon as it is remembered may be considered. However, if it is almost time for the next scheduled dose, skipping the missed dose and continuing the regular schedule is advised. Doubling up on a dose to compensate for the missed dose is generally not recommended.

Q: How quickly does Famocid-40 start working after I take a tablet?

Regulatory documents indicate that the medicine begins to suppress acid production relatively quickly. The onset of the acid-reducing effect occurs within one hour after the oral tablet is taken. The drug's maximum effect is generally observed within one to three hours.

Q: Is Famocid-40 safe to take during pregnancy or while breastfeeding?

Official information indicates that use during pregnancy is typically considered only if the potential benefits are judged to outweigh any potential risk to the fetus. The active ingredient, famotidine, is known to pass into breast milk. Discussion of use during pregnancy or breastfeeding is best held with a healthcare professional.

Q: Can I split the Famocid-40 tablet in half if I want to take a smaller dose?

Regulatory bodies have not evaluated all tablets to ensure that splitting them results in two precise and equal halves. To help ensure the correct amount of medicine is received, splitting a tablet is generally not advised unless specifically recommended by a healthcare provider. Only certain medications are formulated to be safely split.

Q: What should I do if I accidentally take too much Famocid-40 (an overdose)?

If there is suspicion of an overdose of Famocid-40, immediate action is necessary. Seeking emergency medical attention or contacting a Poison Control Center is the recommended course of action for this situation.

Q: Is it safe to drink alcohol while I am taking Famocid-40?

While regulatory labels do not often provide specific guidance on mixing this medication with alcohol, alcohol can sometimes worsen the symptoms of stomach acid-related conditions. Discussion of alcohol consumption while using this medication is best directed to a healthcare provider.

Official Storage and Disposal Requirements

Famocid-40 (famotidine 40 mg) must be stored strictly according to regulatory labeling to maintain its stability.

Storage Condition	Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C.
Environment	Must be kept away from moisture, excess heat, and direct light. Do not freeze.
Packaging	Keep the medicine in its original container, tightly closed.
Security	Must be stored out of the reach of children.

Disposal of Unused Medicine:

Expired or unused Famocid-40 should be disposed of via a medicine take-back program when available. If a take-back program is unavailable, mix the tablets with an unappealing substance, seal the mixture in a plastic bag, and place it in the household trash. Do not flush the medicine down the toilet or sink.